Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐ elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial
Study context
- Population
- Patients with ST-elevation myocardial infarction (STEMI) intended to undergo primary percutaneous coronary intervention (PCI)target
- Participants
- 2,499 patients
- Planned comparison
- Prehospital subcutaneous zalunfiban (2 doses) vs placebo, in addition to standard of care
- Primary endpoint
- Ranked 7-point scale on clinical outcomes (efficacy); severe or life-threatening GUSTO bleeding (safety)
Methodological detailsCELEBRATE, phase 3, double-blinded, placebo-controlled, international, 1:1:1 randomisation, ongoing
- CELEBRATE
- Phase 3
- Double-blinded
- Placebo-controlled
- International
- 1:1:1 randomisation
- Ongoing
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐ elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial. Am Heart J. Published 31 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →